<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-title-group><journal-title>Human Vaccines &#x00026; Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7544963</article-id><article-id pub-id-type="doi">10.1080/21645515.2020.1818522</article-id><article-id pub-id-type="publisher-id">1818522</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of
Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Mini Review</subject></subj-group></article-categories><title-group><article-title>BCG vaccine: a hope to control COVID-19 pandemic amid crisis</article-title><alt-title alt-title-type="left-running-head">Y. S. MALIK ET AL.</alt-title><alt-title alt-title-type="right-running-head">HUMAN VACCINES &#x00026;
IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2832-4854</contrib-id><name><surname>Malik</surname><given-names>Yashpal Singh</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref><xref ref-type="corresp" rid="an0001"/></contrib><contrib contrib-type="author"><name><surname>Ansari</surname><given-names>Mohd Ikram</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ganesh</surname><given-names>Balasubramanian</given-names></name><xref ref-type="aff" rid="aff0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sircar</surname><given-names>Shubhankar</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bhat</surname><given-names>Sudipta</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pande</surname><given-names>Tripti</given-names></name><xref ref-type="aff" rid="aff0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7232-4122</contrib-id><name><surname>Vinodhkumar</surname><given-names>OR</given-names></name><xref ref-type="aff" rid="aff0003"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Prashant</given-names></name><xref ref-type="aff" rid="aff0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4501-7354</contrib-id><name><surname>Iqbal Yatoo</surname><given-names>Mohd</given-names></name><xref ref-type="aff" rid="aff0005"><sup>e</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6897-3472</contrib-id><name><surname>Tiwari</surname><given-names>Ruchi</given-names></name><xref ref-type="aff" rid="aff0006"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Touil</surname><given-names>Nadia</given-names></name><xref ref-type="aff" rid="aff0007"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Shailesh Kumar</given-names></name><xref ref-type="aff" rid="aff0008"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pathak</surname><given-names>Mamta</given-names></name><xref ref-type="aff" rid="aff0008"><sup>h</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1040-3746</contrib-id><name><surname>Sharun</surname><given-names>Khan</given-names></name><xref ref-type="aff" rid="aff0009"><sup>i</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7469-4752</contrib-id><name><surname>Dhama</surname><given-names>Kuldeep</given-names></name><xref ref-type="aff" rid="aff0008"><sup>h</sup></xref></contrib><aff id="aff0001"><label>a</label>Division of Biological Standardization, <institution-wrap><institution>ICAR-Indian Veterinary Research Institute</institution></institution-wrap>, <city>Izatnagar, Bareilly</city>, <state>Uttar Pradesh</state>,
<country>India</country></aff><aff id="aff0002"><label>b</label>Department of Health Research (DHR), Ministry of Health
&#x00026; Family Welfare, Government of India, <institution-wrap><institution>Laboratory Division, ICMR-National Institute of Epidemiology, (Indian
Council of Medical Research)</institution></institution-wrap>, <city>Ayapakkam, Chennai</city>-<state>Tamil Nadu</state>,
<country>India</country></aff><aff id="aff0003"><label>c</label>Division of Epidemiology, <institution-wrap><institution>ICAR-Indian Veterinary Research Institute</institution></institution-wrap>, <city>Izatnagar, Bareilly</city>, <state>Uttar Pradesh</state>,
<country>India</country></aff><aff id="aff0004"><label>d</label>Amity Institute of Virology and Immunology, J-3 Block, <institution-wrap><institution>Amity University</institution></institution-wrap>, <city>Noida</city>, <state>Uttar Pradesh</state>,
<country>India</country></aff><aff id="aff0005"><label>e</label>Division of Veterinary Clinical Complex, Faculty of
Veterinary Sciences and Animal Husbandry, <institution-wrap><institution>Sher-E-Kashmir University of Agricultural Sciences and Technology of
Kashmir</institution></institution-wrap>, <city>Shalimar, Srinagar</city>, <state>Jammu and Kashmir</state>,
<country>India</country></aff><aff id="aff0006"><label>f</label>Department of Veterinary Microbiology and Immunology, <institution-wrap><institution>College of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu
Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU)</institution></institution-wrap>, <city>Mathura</city>, <country>India</country></aff><aff id="aff0007"><label>g</label>Laboratoire De Recherche Et De Bios&#x000e9;curit&#x000e9;, <institution-wrap><institution>H&#x000f4;pital Militaire D&#x02019;instruction Med V De</institution></institution-wrap>, <city>Rabat</city>, <country>Morocco</country></aff><aff id="aff0008"><label>h</label>Division of Pathology, <institution-wrap><institution>ICAR-Indian Veterinary Research Institute</institution></institution-wrap>, <city>Izatnagar, Bareilly</city>, <state>Uttar Pradesh</state>,
<country>India</country></aff><aff id="aff0009"><label>i</label>Division of Surgery, <institution-wrap><institution>ICAR-Indian Veterinary Research Institute</institution></institution-wrap>, <city>Izatnagar, Bareilly</city>, <state>Uttar Pradesh</state>,
<country>India</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Yashpal Singh Malik <email xlink:href="mailto:malikyps@yahoo.com">malikyps@yahoo.com</email> Division of Biological
Standardization, <institution-wrap><institution>ICAR-Indian Veterinary Research Institute</institution></institution-wrap>, <city>Izatnagar, Bareilly</city>, <state>Uttar Pradesh</state>,
<country>India</country></corresp><fn id="an0002"><p>ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India Kuldeep
Dhama, PhD <email xlink:href="mailto:kdhama@rediffmail.com">kdhama@rediffmail.com</email> Division of Pathology, ICAR-Indian Veterinary Research
Institute, Bareilly, India</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>9</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>9</lpage><permissions><copyright-statement>&#x000a9; 2020 Taylor &#x00026; Francis Group, LLC</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Taylor &#x00026; Francis</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted
re-use and analyses in any form or by any means with acknowledgement of the original
source. These permissions are granted for the duration of the COVID-19 pandemic or until
permissions are revoked in writing. Upon expiration of these permissions, PMC is granted
a perpetual license to make this article available via PMC and Europe PMC, consistent
with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="KHVI_0_1818522.pdf"/><abstract><title>ABSTRACT</title><p>COVID-19 caused by the virus SARS-CoV-2 has gripped essentially all countries in the
world, and has infected millions and killed hundreds of thousands of people. Several
innovative approaches are in development to restrain the spread of SARS-CoV-2. In
particular, BCG, a vaccine against tuberculosis (TB), is being considered as an
alternative therapeutic modality. BCG vaccine is known to induce both humoral and adaptive
immunities, thereby activating both nonspecific and cross-reactive immune responses in the
host, which combined could effectively resist other pathogens including SARS-CoV-2.
Notably, some studies have revealed that SARS-CoV-2 infectivity, case positivity, and
mortality rate have been higher in countries that have not adopted BCG vaccination than in
countries that have done so. This review presents an overview of the concepts underlying
BCG vaccination and its nonspecific immuological effects and protection, resulting in
&#x02018;trained immunity&#x02019; and potential utility for resisting COVID-19.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>COVID-19</kwd><kwd>sars-CoV-2</kwd><kwd>tuberculosis</kwd><kwd>bcg vaccine</kwd><kwd>immune response</kwd><kwd>cross-reactivity</kwd><kwd>trained immunity</kwd></kwd-group><counts><fig-count count="2"/><ref-count count="82"/><page-count count="9"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001" disp-level="1"><title>Introduction</title><p>Coronaviruses (CoVs) are generally regarded as nonlethal human pathogens, mostly causing
common cold.<sup><xref rid="cit0001" ref-type="bibr">1</xref></sup> However, during the last
18&#x000a0;years, two human pathogenic CoVs, namely severe acute respiratory syndrome Coronavirus
(SARS-CoV) and Middle-East respiratory syndrome Coronavirus (MERS-CoV), have caused
epidemics that originated in China (2002) and Saudi Arabia (2012), respectively, and spread
over to several countries with high morbidity and mortality.<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup> Thus, in the recorded history of humans, the existing
SARS-CoV-2 outbreak is the third human CoV outbreak. SARS-CoV-2 has higher genetic
relatedness with SARS-CoV (nearly 80%) than with MERS-CoV (nearly 50%).<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup></p><p>COVID-19, a <bold><italic>Co</italic></bold>rona <bold><italic>Vi</italic></bold>rus <bold><italic>D</italic></bold>isease, emerged in
early December 2019 and is caused by a novel CoV named SARS-CoV-2 due to the association of
COVID-19 symptoms with those of severe acute respiratory distress (SARD) and the resemblance
of COVID-19 with the previous human CoV disease, SARS, that originated in Guangdong region
of China in 2002 and spread over 27 countries before its termination in mid-2003.<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup> Since the first COVID-19 case was confirmed
in Wuhan city of Hubei province in China on December 7, 2019, COVID-19 has gripped
essentially all countries in the world, infected over 25 million confirmed people and killed
almost one million people (WHO COVID-19 Situation report-201, August 8, 2020).<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> Consequent to its panic spread, morbidity,
mortality, economic significances, COVID-19 was declared by the World Health Organization
(WHO) as a Public Health Emergency of International Concern (Pandemic) on February 1, 2020
and on March 11, 2020 as pandemic.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup>
Though the origin source of SARS-CoV-2 has not been traced to date, the virus is assumed to
be of zoonotic origin (from animals), primarily bats, followed by maintenance of virus in
the ecosystem through human-human transmission cycle. A few of the ongoing studies have
further expanded COVID-19 hosts, including dogs, cat, and few wild animals.<sup><xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0007" ref-type="bibr">7</xref></sup></p><p>COVID-19, in comparison to SARS, has different epidemiological features as reflected in
demographic studies. SARS-CoV-2 can replicate in both upper and lower respiratory tracts,
causing mild or no symptoms in the early stages of infection.<sup><xref rid="cit0008" ref-type="bibr">8</xref>&#x02013;<xref rid="cit0010" ref-type="bibr">10</xref></sup> Thus,
a person infected with SARS-CoV-2 can spread the infection in early-stages or during the
incubation period, causing difficulty in controlling the pandemic. In contrast, SARS-CoV is
transmitted when the patients are severely ill, and almost no transmission occurs in the
early stage.<sup><xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0012" ref-type="bibr">12</xref></sup></p><p>Therefore, the current COVID-19 syndemic is extreme and harder to control than the previous
SARS outbreak. In the absence of any suitable treatment for SARS-CoV-2 infection, only
supportive care is being provided to the patients of COVID-19.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> Different types of therapies that have been used before
for the treatment of MERS-CoV and SARS-CoV infections or other viral diseases are being
considered for treatment of SARS-CoV-2 infection, as it is a new disease and lack any
standard therapeutic option. These therapies include immunosuppressants, steroids,
anti-viral drugs, plasma from recuperated patients, Chinese medications, and repurposed
drugs. Pharmaceutical companies are in a race to produce antibodies and vaccines against
SARS-CoV-2.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0014" ref-type="bibr">14</xref></sup></p><p>Bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccine is widely used in infancy as prevention against
tuberculosis (TB). Epidemiological and randomized studies suggest that BCG vaccine provides
a protective effect against infant mortality through nonspecific heterologous protection to
other infections<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> maybe through
innate immune epigenetic mechanisms.<sup><xref rid="cit0015" ref-type="bibr">15</xref>&#x02013;<xref rid="cit0017" ref-type="bibr">17</xref></sup> Exposure to BCG vaccine can reduce the
severity of COVID-19 and may lower mortality, and thus, it may be helpful in development of
therapeutic or preventive strategies that can impact SARS-CoV-2 infections.</p><p>This review provides a comprehensive summary on the beneficial effects and protection
offered by the BCG vaccine against COVID-19. As of now, only a limited approved therapeutics
and/or vaccines are available/or are in final clinical trials for disease control, and as a
result, the COVID-19 pandemic has become a huge threat/crisis to global public
health.<sup><xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0018" ref-type="bibr">18</xref></sup></p><sec id="s0001-s2001" disp-level="2"><title>SARS-CoV-2/COVID-19 treatment alternatives</title><p>In the absence of an approved, safe and effective vaccine or a standard therapeutic
option for mitigating the COVID-19 pandemic, scientists and public health experts have
suggested the use of currently existing licensed vaccines/drugs, i.e., called repurposing
of vaccines/drugs (used against other bacterial/viral infections) such as BCG
vaccine,<sup><xref rid="cit0019" ref-type="bibr">19</xref></sup> antimicrobials,
didanosine<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> and
hydroxychloroquine,<sup><xref rid="cit0021" ref-type="bibr">21</xref>,<xref rid="cit0022" ref-type="bibr">22</xref></sup> antiparasitics, ivermectin<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup> or combination of hydroxychloroquine and
ivermectin,<sup><xref rid="cit0024" ref-type="bibr">24</xref></sup> antibiotics,
azithromycin<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup> or antiviral
drugs ART<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup> like
lopinavir/ritonavir, favipiravir, and remdesivir<sup><xref rid="cit0026" ref-type="bibr">26</xref>&#x02013;<xref rid="cit0028" ref-type="bibr">28</xref></sup>
for the treatment of COVID-19.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup>
Similarly, many advanced and novel therapeutics are also being tested for the treatment of
COVID-19, including CAR T-cell,<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup>
stem-cell,<sup><xref rid="cit0031" ref-type="bibr">31</xref></sup> RNA Synthesis
inhibitors,<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup> Protease
Inhibitors,<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup> monoclonal
antibodies,<sup><xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0035" ref-type="bibr">35</xref></sup> and immunoglobulins-based therapy.<sup><xref rid="cit0036" ref-type="bibr">36</xref></sup></p></sec><sec id="s0001-s2002" disp-level="2"><title>COVID-19 vaccines-update</title><p>A new mRNA vaccine (mRNA-1273) was developed by a clinical stage biotechnology company,
named Moderna, Inc., USA, which is a pioneering messenger RNA (mRNA) therapeutics and
vaccines firm, has initiated Phase-I clinical trials on March 16, 2020 against SARS-CoV-2.
This mRNA vaccine encoding for a prefusion stabilized form of the Spike (S) protein of
SARS-CoV-2.<sup><xref rid="cit0037" ref-type="bibr">37</xref></sup> The Phase-I study
evaluated the safety and immunogenicity of three dose levels of mRNA-1273 (25, 100, and
250&#x000a0;&#x003bc;g) administered on a two-dose vaccination schedule, given 28&#x000a0;days apart in 45 healthy
adults enrolled in the study. The phase 3 clinical trial of mRNA-1273 has started in the
U.S. Clinical research site enrolling approximately 30,000 adult individuals.</p><p>Ad5-nCoV is the first COVID-19 vaccine in a clinical trial in China.<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup> The vaccine developed by CanSinoBIO&#x02019;s
adenovirus-based viral vector vaccine technology platform. In the human trial of the
vaccine, it is found safe and induces a rapid immune response. The AZD1222 CoV vaccine,
formerly known as ChAdOx1 nCoV-19, developed from ChAdOx1 virus. The ChAdOx1 vaccine is in
clinical trials to prevent infection of SARS-CoV-2. AstraZeneca Plc announced it selected
Emergent BioSolutions to produce the 300 million doses of the COVID-19 vaccine candidate.
The oxford- AstraZeneca in the phase I/II trial tolerated and generated strong immune
responses in all the participants in the United Kingdom. The vaccine has entred in its
final trial in Brazil along with studies going on in the United Kingdom and South Africa.
Similarly Pfizer also trigerred strong T-cell response in phase I/II and has entered the
pase III trial. The Sinovac Biotech Ltd. developed the CoronaVac SARS-CoV-2 vaccine based
on an inactivated virus. Sinovac Biotech got approval from Chinese authorities to conduct
both the phase-I and phase-II human clinical trials for CoronaVac in China. DNA vaccine
INO-4800 designed to prevent SARS-CoV-2 from infecting humans is under phase-I/II clinical
trial by INOVIO and Seoul National University Hospital and is expected to be available by
November 2020.<sup><xref rid="cit0039" ref-type="bibr">39</xref></sup></p><p>The Johnson and Johnson and Janssen Pharmaceutical research teams, in collaboration with
Beth Israel Deaconess Medical Center, part of Harvard Medical School, have selected its
lead vaccine candidate Ad26-COV2-S, recombinant for prevention of coronavirus infection.
They have started the Phase-I/II a first-in-human clinical trial of its investigational
SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. The NVX-CoV2373 is a prefusion protein CoV
vaccine candidate made using Novavax&#x02019;s proprietary nanoparticle technology, Matrix-M,
which is an adjuvant to enhance immune responses and stimulate high levels of neutralizing
antibodies. In preclinical trials, NVX-CoV2373 showed efficient binding with receptors of
the SARS-CoV-2. Sanofi-GSK using a combination of innovative technologies developed an
adjuvanted SARS-CoV-2 vaccine to prevent COVID-19 disease. The companies may start phase-I
clinical trials in the second half of 2020 and, aim to complete the development of the
vaccine by the second half of 2021. Vaxart develop an oral H1 influenza vaccine targeting
the SARS-CoV-2. The phase-II clinical study showed that oral H1 flu tablet vaccine
protects against influenza infection after just one dose. Based on these results, it is
considered to protect against mucosal respiratory viruses such as SARS-CoV-2.</p></sec><sec id="s0001-s2003" disp-level="2"><title>Tuberculosis and bacillus calmette&#x02013;gu&#x000e9;rin (BCG) vaccine</title><p>An important potential approach to COVID-19 control is the use of BCG vaccine<sup><xref rid="cit0040" ref-type="bibr">40</xref></sup> for COVID-19, which was developed by
Jean-Marie Canille Guerin and Albert Calmette around 100&#x000a0;years back for immunization
against Tuberculosis (TB), one of the most dreaded human diseases caused by <italic>M. tuberculosis</italic> (MTB). TB is predominant in developing countries
and connected with poverty status, and control of TB is at least an issue of equity and
human rights.<sup><xref rid="cit0041" ref-type="bibr">41</xref></sup> In areas with high
burden of TB, control strategies for TB are overpowered by the rising cases of TB,
occurring in parallel with HIV/AIDS pandemic.<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup></p><p>Further, the situation is being complicated due to the emergence of drug resistance among
Mycobacterium tuberculosis, i.e., multidrug resistant tuberculosis (MDR-TB) or extensively
drug resistant tuberculosis (XDR-TB). TB is endemic, and no country is TB-free in the
world. It is assessed that 33% of the world population is infected with <italic>M. tuberculosis</italic> but shows no symptoms, and only 5&#x02013;10% develop TB
during their lifetime.<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup> In high
burden countries, the annual risk of TB infection in children is estimated to be 0.5&#x02013;2%.
Childhood deaths from TB are commonly caused by meningitis or disseminated disease. BCG
vaccine is a live, debilitated strain of <italic>M. bovis</italic>, which is
closely related to <italic>M. tuberculosis</italic>, but the bacterium is
commonly responsible for causing TB in cattle, known as bovine-TB. The BCG vaccine has
existed for more than 100&#x000a0;years and is one of the most commonly used vaccines even today,
worldwide.<sup><xref rid="cit0044" ref-type="bibr">44</xref></sup></p></sec><sec id="s0001-s2004" disp-level="2"><title>BCG vaccine coverage</title><p>BCG vaccine was included into the Expanded Programme on Immunization (EPI) (WHO) in 1974,
and has been used as the primary TB vaccine since then. Every year, around 100 million
children are given BCG vaccine worldwide.<sup><xref rid="cit0045" ref-type="bibr">45</xref>,<xref rid="cit0046" ref-type="bibr">46</xref></sup> Among children, BCG
prevents infection by most of the severe forms of TB, and reduces the incidence of miliary
and meningeal TB by around 85% and TB-related deaths by 66%.<sup><xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0048" ref-type="bibr">48</xref></sup> BCG has
been prescribed during childhood in nations having a high burden of TB for decades.
Currently, 152 low- and middle-income countries (LMIC) have adopted universal child
vaccination policy at birth or in the first week of birth.<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup></p><p>The data on BCG vaccination is available from 180 countries, and among them currently,
157 countries recommend a policy of universal BCG vaccination. The remaining countries,
either due to questionable efficacy of the BCG vaccine in protection against TB infection
or due to reduction in incidence of TB, have either stopped BCG vaccination or do not
suggest mass BCG immunization and rather provide vaccination only to &#x0201c;at-risk&#x0201d; groups.
Some countries, like the United Kingdom, run programs for universal BCG vaccination. In
contrast, others, like the United States and Canada, either recommend BCG for high-risk
groups or do not support nationwide BCG vaccination (<ext-link ext-link-type="uri" xlink:href="https://en.wikipedia.org/wiki/BCG_vaccine">https://en.wikipedia.org/wiki/BCG_vaccine</ext-link> 2020).</p><p>During 1940&#x02013;1980, many nations started the program of BCG vaccination; however, a few
nations, such as, Romania and Uzbekistan, had started vaccination much earlier in 1928 and
1937, respectively, while few African countries, for example, Nigeria and Sierra Leone,
began to provide BCG vaccination as late as in 1991 and 1990, respectively. To date, nine
countries have stopped the program of universal BCG vaccination. Spain and Denmark were
among the first countries to stop in 1981&#x02013;1986, while Austria and Germany halted the
vaccination in 1990 and 1998, respectively. The remaining nations, including the Isle of
Man, Slovenia, the United Kingdom, Finland, and France, stopped their respective BCG
vaccination programs somewhere between 2005 and 2007. While some of these nations have
stopped vaccination programs universally, many of them continue to provide BCG vaccination
to high-risk groups or individuals, including those involved in occupations with high-risk
of exposure to TB and children born in an environment with high burden of TB.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup></p></sec><sec id="s0001-s2005" disp-level="2"><title>BCG vaccine immunomechanisms</title><p>The live attenuated BCG-TB vaccine proficiently induces nonspecific cross-protection
against pathogens, which may be different from the cause of target disease.<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> BCG vaccination in children reduces
mortality and elicits an improved innate immune response against different microorganisms
in addition to <italic>M. tuberculosis</italic>, such as <italic>Staphylococcus aureus</italic> and <italic>Candida albicans</italic>. This
nonspecific immune protection is provided by the innate immune cells, including monocytes
and natural killer cells, and this development does not depend on T or memory B cells. The
monocytes are epigenetically reprogrammed at the site of immunization such that there is
histone modification in the promoter region of genes encoding proinflammatory cytokines
and hence, there is a long-term change in their ability to respond to novel stimuli. These
monocytes exhibit enhanced production of cytokines like IL1&#x003b2;, IFN&#x003b3; and TNF&#x003b1; in response to
infection with several different pathogens.<sup><xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0053" ref-type="bibr">53</xref></sup> The phenomenon of
producing a memory-like response in innate immune cells is known as &#x0201c;trained
immunity.&#x0201d;<sup><xref rid="cit0054" ref-type="bibr">54</xref></sup></p><p>BCG was first used as an immunotherapy for the treatment of bladder cancer around
40&#x000a0;years ago.<sup><xref rid="cit0055" ref-type="bibr">55</xref></sup> BCG being a liquid
drug can be deposited directly into the bladder through a catheter. Immunotherapy is used
to induce the immune system for attacking cancer cells. Several immune molecules and cell
types were indetified involved<sup><xref rid="cit0056" ref-type="bibr">56</xref>&#x02013;<xref rid="cit0058" ref-type="bibr">58</xref></sup> in the action of BCG. It is apparent
that the effects of BCG on the immune system are complex, multifactorial, and likely to
evolve. The data suggest that the anticancer effects of BCG are due to the direct action
on tumor cells by BCG and the host&#x02019;s immune response.<sup><xref rid="cit0058" ref-type="bibr">58</xref></sup> The activation of the immune system led to recognition
and subsequent destruction of tumor cells through nonspecific and specific cell-mediated
mechanisms.<sup><xref rid="cit0057" ref-type="bibr">57</xref></sup>The concept of
trained immunity was first proposed by Netea et al.<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> and is defined as an improved nonspecific response by
the innate immune cells to secondary infection caused by different or same
microorganisms.<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> In adult
humans, BCG vaccine induces trained phenotype in monocytes, leading to an increase in
their capacity to secrete proinflammatory cytokines, which provide nonspecific protection
against <italic>S. aureus</italic> and <italic>C.
albicans</italic>.<sup><xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0060" ref-type="bibr">60</xref></sup> BCG vaccination also induces the adaptive immune response, which leads
to activation of both CD4+&#x000a0;and CD8&#x000a0;+&#x000a0;T cells<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> and increased production of interferon-gamma (IFN-&#x003b3;), which increases
the anti-mycobacterial activity of macrophages.<sup><xref rid="cit0062" ref-type="bibr">62</xref></sup> Further, cytokines help in B cell activation and successive
antigen-specific antibody production by plasma cells. After vaccination, a pool of
mycobacteria-specific CD8&#x000a0;+&#x000a0;T cells multiplies, and remains in the peripheral blood for
around 10&#x000a0;weeks. Beyond providing protection against TB, BCG vaccine also has some other
clinical applications, particularly in immunotherapy, such as treatment of autoimmune
diseases like type-1 diabetes and various cancers including melanoma.<sup><xref rid="cit0054" ref-type="bibr">54</xref></sup></p><p>BCG induced protection is also reported especially in case of respiratory virus
infections. A study on BCG vaccination done in South Africa and in Guinea-Bissau reported
up to 70% reduction in the incidence of respiratory tract infection including that of
Respiratory Syncytial virus. A similar study showed the protective efficacy of BCG
vaccination against influenza A virus and Herpes simplex virus (HSV) where it was shown
that peritoneal macrophages are significantly activated by the vaccination to produce
protective cytokines.<sup><xref rid="cit0063" ref-type="bibr">63</xref></sup></p><p>The two types of immune responses are innate and adaptive immune responses <xref ref-type="fig" rid="f0001">Figure 1</xref>. In innate immune system, cells recognize and
respond to pathogens in a nonspecific manner. Various types of cells, including B and T
lymphocytes, dendritic cells, eosinophils, macrophages, mast cells, and neutrophils are
involved in an innate immune response.<sup><xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0064" ref-type="bibr">64</xref></sup> Antigen presenting
cells (APCs) kill the invading pathogens by engulfing and digesting them. Later, they move
to the lymph node, where the antigens are presented to the na&#x000ef;ve T cells, resulting in
differentiation of T helper cells into different effector T cells (CD8&#x000a0;+&#x000a0;T Cells/Th1;
CD4&#x000a0;+&#x000a0;T Cells/Th2).</p><p>The immediate defense against an infection is provided by the innate immune system and is
vital for effective initiation of adaptive immunity.<sup><xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></sup> In
contrast, adaptive immunity is mediated by T cells, B cells, and memory cells and it
provides antigen-specific responses. T and B cells recognize a variety of antigens through
unique T-cell receptors (TCRs) and B-cell receptors (BCRs), respectively. The activation
of T and B cells lead to the development of killer cytotoxic T cells (cellular
immunity)<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup> and production of
antibodies by differentiated plasma B cells (humoral immunity).<sup><xref rid="cit0068" ref-type="bibr">68</xref></sup> The immune response is initiated by the interaction
between the innate immune cells and adaptive immune system. <fig id="f0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Innate and adaptive immune response to a pathogen (Virus/Bacteria/Parasite).</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="KHVI_A_1818522_F0001_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="KHVI_A_1818522_F0001_PB"/></alternatives><attrib>(1) Recruitment of antigen presenting cell (APC) at the injection site. (2)
Enhancement of antigen uptake. (3) Enhancement of Th2 response. (4) Enhancement of
humoral immune response. (5) Improvement in inflammasomes of macrophages.</attrib></fig></p><p>A new live attenuated TB vaccine, named MTBVAC, has been found to induce not only
specific T-cell immunity, but also long-term epigenetic and metabolic reprogramming of the
cells of innate immune system through a process termed &#x02018;trained immunity.&#x02019;<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> The trained immunity has been found to
confer protection against experimental lethal pneumonia infections.<sup><xref rid="cit0070" ref-type="bibr">70</xref></sup> The modified MTBVAC vaccine promotes
proinflammatory genes, and facilitates an enhanced response after nonrelated bacterial
stimuli.</p><p>The shift in immune response toward cellular or humoral immunity occurs through
stimulation of phagocytes and the cytokine environment <xref ref-type="fig" rid="f0002">Figure 2</xref>, which aids in differentiation of na&#x000ef;ve CD4&#x000a0;+&#x000a0;T cells into TH1 and/or
TH2 cells.<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> Appropriate stimulation
of TH1 immune responses is needed to achieve the therapeutic outcome of BCG vaccine.
Inhibition of TH1 and TH2 immune responses occurs through (interleukin) IL-10 and
(interferon-gamma) IFN-&#x003b3;, respectively. Blocking IL-10 or inducing IFN-&#x003b3; can lead to
TH1-dominated immunity that is essential for BCG-mediated heterologous immunity.<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup>
<fig id="f0002" fig-type="figure" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Schematic representation of BCG-triggered immune response in cell-mediated
immunity.</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="KHVI_A_1818522_F0002_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="KHVI_A_1818522_F0002_PB"/></alternatives><attrib>Activation of phagocytes and a new cytokine environment leads to differentiation
of na&#x000ef;ve CD4&#x000a0;+&#x000a0;T cells into TH1 and/or TH2 cells, which direct the immune response
toward cellular or humoral immunity, respectively. The therapeutic effect of BCG
depends on proper induction of TH1 immune response. IL-10 inhibits TH1 immune
response, whereas IFN-&#x003b3; inhibits TH2 immune response. Blocking IL-10 or inducing IFN-&#x003b3;
can lead to TH1-dominated immunity, which is essential for BCG-mediated heterologous
immunity.</attrib></fig></p></sec><sec id="s0001-s2006" disp-level="2"><title>BCG vaccine based alternative treatment of COVID-19</title><p>Due to the unavailability of a standard and/or specific drug or an appropriate safe and
effective approved vaccine to combat in the battle against COVID-19 pandemic, globally
researchers are working to find some alternative therapeutics. Usually, the mechanisms
outlined for the release of a safe and effective molecule/drug for use in healthcare
settings require a long chain of safety, efficacy and feasibility checks. Thus, a
drug/vaccine already in use holds better promise in current emergency and global public
health crisis. Therefore, scientists and pharmacologists across the globe are searching
for vaccines/drugs in use to flatten the explosive graph of SARS-CoV-2-affected population
worldwide.</p><p>The elderly population is more susceptible than younger people are to many diseases,
including influenza, pneumococcal and zoster. In addition, the information on the
occurrence of COVID-19 worldwide has provided a strong indication of elderly population
more prone to the disease. This increased susceptibility is generally believed to be a
result of the aging immune system, which is manifest in lower levels of immune responses
to such vaccines in terms of both antibody levels as well as cellular immunity. The
figures for age susceptibility pattern are almost similar in SARS-CoV, MERS-CoV, and the
current SARS-CoV-2 infections.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup>
Even if infection is established in young people, symptoms remain mild, and recovery is
fast. Salman and Salem<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup> summarized
the influence of routine childhood immunization (usually five to six vaccines) on
protection against COVID-19. A few vaccines such as Hepatitis B, rubella, mumps,
poliomyelitis, and varicella also lead to development of immunity against SARS-CoV-2, and
thereby, provide protection against the invasion of the lung cells. The mechanisms have
revealed that TH1 cells (CD4+) are stimulated by killed or inactivated vaccines. The
activated TH1 cells then lead to an increase in the production of IFN-&#x003b3;, IL-2, and IL-12,
which aid in maturation of killer T cells and increase the cytotoxic activity of NK cells,
thereby, terminating the virus-infected cells.</p><p>A study published by the New York Institute of Technology has proposed BCG vaccine as an
alternative treatment that is in use to treat TB in humans since 1921.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> In the study, analysis of different
countries based on wide variation in the intensity of the disease has revealed that in the
countries where BCG vaccine is given to newborns and children to prevent childhood TB, the
vaccine seems to offer cross-protection against COVID-19.<sup><xref rid="cit0051" ref-type="bibr">51</xref>,<xref rid="cit0073" ref-type="bibr">73</xref></sup> The study
reported that countries that have either stopped or do not provide universal BCG
vaccination to children, including the United States, Italy, Spain, and France, have more
COVID-19 cases and deaths as compared to the countries having universal BCG immunization
program. Middle-high- and high-income countries that currently have universal BCG policy
have reported 0.78&#x000a0;&#x000b1;&#x000a0;0.40 deaths per million. A significant difference can be noticed
while comparing COVID-19 mortality data from middle-high- and high-income countries that
never had a universal BCG policy with the data from countries that have BCG vaccination in
their regular immunization programme. The former have a significantly higher mortality
rate, 16.39&#x000a0;&#x000b1;&#x000a0;7.33 deaths per million people. Moreover countries like Japan and Russia
where the vaccine composition includes the original BCG strain have shown low per capita
death rate compared to European countries where modified BCG strain is used for
vaccination.<sup><xref rid="cit0074" ref-type="bibr">74</xref></sup> But Brazil is the
exception with having second highest number of cases and mortality. The reason for this
high number is not clear. Some of the low income countries with universal BCG policy have
reported zero deaths per million.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup></p><p>In another study, Singh and Gandharva<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> analyzed data on BCG vaccination from 81 countries, including Canada,
Italy, and the United States. The results of the study revealed that there is higher
COVID-19 infectivity (11.2% versus 8.53%), case positivity (1043.9 versus 172.4), and
deaths (48.9 versus 4.3) per million population in countries that have not adopted BCG
vaccination as compared to those that use BCG vaccines. As stated previously, the higher
protection against COVID-19 morbidity and mortality observed in countries that provide BCG
vaccination during childhood might be due to provoking of both nonspecific and
cross-protective immune responses.<sup><xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>,<xref rid="cit0076" ref-type="bibr">76</xref></sup> The trained immunity
conferred by BCG vaccination include the enhanced expression of certain resistance factors
like IL-&#x003b2; which might have a major role in reducing the level of viremia in infected hosts
as shown in case of yellow fever virus administration.<sup><xref rid="cit0068" ref-type="bibr">68</xref></sup></p><p>The number of confirmed cases and deaths due to COVID-19 in the United States, Italy, and
Spain has outnumbered that of China, which was the epicenter of the outbreak of the
disease first identified in Wuhan city in the beginning of December 2019. Why did COVID-19
spread in China, despite the country having a universal BCG strategy since the 1950s? The
reason may be that the virus spread unexpectedly and rapidly without it being recognized
as a new virus and one capable of high-level interpersonal spread, while measures were not
taken initially to restrain its spread. In addition, banning and weakening of the TB
prevention and treatment agencies during Cultural Revolution (1966&#x02013;1976) may also be
responsible. This may have produced a pool of potential hosts that could be affected by
SARS-CoV-2 and may have played a viral role in spread of COVID-19 transmission. Currently,
the condition in China appears to be improving promisingly.<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup></p><p>In India, childhood BCG vaccination began in 1949, and at present, around 97% of 26
million children born in India are administered free BCG vaccine during their first week
of birth.<sup><xref rid="cit0077" ref-type="bibr">77</xref>,<xref rid="cit0078" ref-type="bibr">78</xref></sup> Among all vaccines, BCG is given in highest number to
children under five years of age under the universal immunization programme. It is
generally given to newborn babies at birth; however, if vaccination is missed at birth, it
can be given any time until the age of one. According to the data from the Ministry of
Health and Family Welfare, Government of India, the percentage of children vaccinated with
BCG went up from 92% in 2015&#x02013;16 to the current 97%. BCG vaccination is above 95% in all
the states of India. In India, since the first COVID-19 case was confirmed on January 30,
2020 (Kerala), and the first COVID-19 fatality was confirmed on March 11, 2020
(Karnataka), the total number of confirmed cases has reached to approximately 2.1 million
with nearly 43,000 deaths in the following 191&#x000a0;days (WHO Situation Report-201, India as on
August 8, 2020).<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> The question
before medical researchers is that will BCG vaccination, which had been started in India
long ago, help in preventing COVID-19 cases and reducing the death toll?</p><p>According to a study published in medRxiv, the preprint health sciences server, BCG
vaccination seems to be contributing significantly in reduction of number of COVID-19
deaths, with the most substantial reduction in deaths observed in countries that had
adopted a BCG vaccination policy earlier, suggesting that there might be less COVID-19
cases and mortality in those countries.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> Though it is early to declare and would need further investigations
before a conclusion is reached, the statistical figures on BCG vaccination in India during
the early 1950s with target coverage of 80% indicate that the country might benefit from
the presence of enhanced acquired innate immunity in a large population. Nevertheless, the
low- and middle-income countries have reported 0&#x02013;0.78 deaths per million, while the
countries that adopted a universal BCG policy later than other countries, like Iran in
1984, have exhibited a high death rate, which is contrary to the hypothesis that BCG
protects the vaccinated population against COVID-19. The current population of India is
1339.2 million, and to date, India has reported 0.42 deaths per million, which is in
accordance with the calculations and range provided by Miller and coworkers.<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup> Based on the current situation and data
available, we can say that BCG vaccination may have an influence on the number of COVID-19
cases and deaths and might provide protection against COVID-19 but to show the actual
causality between BCG vaccine and severity of COVID-19, the scientists must confirm the
Bradford Hill Criteria which include specificity, reversibility, temporality, and
experiment.<sup><xref rid="cit0079" ref-type="bibr">79</xref></sup> There have been
inconsistencies in data related to COVID-19 collected from different countries,;
therefore, its important to have a proven result for the use of BCG vaccine in context of
COVID-19. Toward this end, it is reported that three clinical trials, with an aim to
confirm the role of BCG vaccine in protection against COVID-19, have been
intiated.<sup><xref rid="cit0052" ref-type="bibr">52</xref>,<xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0080" ref-type="bibr">80</xref></sup> The clinical trial planned by Max Plank
Institute for Infection Biology in Berlin include the use of genetically modified version
of BCG while other two trails have been planned in Australia and Netherland. However, some
group also suggest that COVID-19 vaccination should include multiple-doses of BCG
vaccine.<sup><xref rid="cit0019" ref-type="bibr">19</xref></sup></p></sec><sec id="s0001-s2007" disp-level="2"><title>Clinical manifestations of COVID-19 cases (morbidity and moratlity) around the
world</title><p>The clinical manifestations among the COVID-19 positive cases varies greatly between
developed and developing countries.</p><p>As per the latest WHO COVID-19 Situation Report-201<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> (as on August 8, 2020), the number of laboratory
confirmed cases are on the raise among the developed nations and they are currently
classified under community transmission phase viz. the United States, and European
countries, while the United States is leading the count with more than 4.8 million
confirmed positive cases. But on the other hand, the developing countries are still
classified under cluster of cases phase. Here, at the developing nations, under-reporting
of cases, number of tests carried out for the suspected and confirmed cases, misdiagnosis
and missed diagnosis may be considered as part of limitations while comparing the data
between developed and developing nations, worldwide.</p><p>Similarly, as per the WHO COVID-19 Situation Report-201<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> (as on August 8, 2020) have reported the highest number
of deaths due to COVID-19 among the developed nations viz. the United States, about
160,000 deaths followed by the Brazil, Mexico, the United Kingdom, Italy, France, Spain,
etc. The mortality rate among the developing countries, very low as compared to the
developed nations. The data from the developing countries needs to be assessed on a
periodic intervals, and as the cause of death also need to be confirmed before declaring
the same amid COVID-19 crisis.</p></sec><sec id="s0001-s2008" disp-level="2"><title>R&#x00026;D/Clinical trials on BCG vaccination among health-care workers against
COVID-19</title><p>In the United States, a group of researchers from the academic and research institutions
have initiated a Clinical trial titled &#x0201c;BCG Vaccine for Health Care Workers (HCW) as
Defense Against COVID 19 (BADAS)&#x0201d;.<sup><xref rid="cit0081" ref-type="bibr">81</xref>,<xref rid="cit0082" ref-type="bibr">82</xref></sup> [U.S. National Library of Medicine,
ClinicalTrials.gov website: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04348370">https://clinicaltrials.gov/ct2/show/NCT04348370</ext-link>]. In summary the clinical
trials confirms the investigators hypothesize that BCG vaccination can reduce HCW
infection and disease severity during the epidemic phase of SARS-CoV-2. Similar studies
are underway in many countries including Murdoch Children&#x02019;s Research Institute in
Australia (MCRI), and India. Since the studies are ongoing, we have to wait to get the
concrete conclusion till the end of the study with analyzed data and report with a
positive hope to mitigate COVID-19, which is on top priority, globally to avert this
public health crisis.</p></sec><sec id="s0001-s2009" disp-level="2"><title>Conclusion and prospects</title><p>Due to the enormous impact of the COVID-19 pandemic worldwide, the early research that
was mainly focused on the epidemiology and clinical manifestation has turned toward early
and accurate diagnosis as well as timely development of an appropriate therapeutic methods
and vaccines to control the escalating SARS-CoV-2 infections. Until a suitable cure is
available, alternatives like BCG vaccine, which is used for preventing childhood TB, may
also be used to provide additional cross-protection against COVID-19 and is a topic of
discussion. The initial observations from the countries that have stopped and do not
provide childhood BCG vaccination, including the United States, Italy, Spain, and France,
revealed that these countries are reporting more COVID-19 cases and deaths than the
countries that provide universal BCG vaccination. This higher protection against COVID-19
from the BCG vaccine is assumed to be due to nonspecific and cross-protective
immunity.</p><p>The signifying advantage of BCG vaccination, an early life immunization with unique
formulations, is an unanticipated reduction (&#x0223c;50%) in all-cause mortality, especially in
low-birth weight males, greatly exceeding that attributable to TB prevention. This
mortality benefit has been related to prevention of sepsis and respiratory infections,
suggesting that BCG vaccine induces &#x0201c;heterologous&#x0201d; cross-protection against unrelated
pathogens. The nonavailability of a suitable vaccine or therapeutic option to mitigate the
COVID-19 pandemic is forcing researchers and public health experts to be assertive on the
use of BCG vaccine to control the COVID-19 disease caused by SARS-CoV-2 especially the
adult and old-age population. It is unclear whether the vaccine given to old-age
population will make adequate or similar immunological response as delivered to the young
age population. The ongoing clinical trials of BCG in health care workers are anticipated
to provide an insight on the usage of TB vaccine in old-age population against
COVID-19.</p><p>The data and statistics available from limited investigations have revealed a correlation
between the use of BCG vaccination and protection from COVID-19. However, further studies
are required to judge the prophylactic and/or therapeutic significance of BCG vaccine
against COVID-19 and to strengthen the evidence of the molecular mechanisms proving this
hypothesis. Considering the global need to restrain the COVID-19 emergence and
transmission, scholars at Murdoch Children&#x02019;s Research Institute in Australia (MCRI) are
underway to explore the use of BCG vaccine-generated cross-protection in countering
COVID-19.</p><p>Some important factors that must be considered include the shortage of BCG vaccines,
appropriate time of vaccination for such protections and longivity of heterologous
immunity conferred by BCG vaccine. In this regard, Japanese Society for Vaccinology
recently raised a concern with a view that indiscriminate use of BCG vaccine might create
a shortage of the vaccine for regular immunization schedule which may lead to the spread
of tuberculosis. This review has provided information that might help to control the
current COVID-19 pandemic; however, further extensive and comprehensive research is
required for the development of valid and reliable methods for managing the current public
health pandemic in both short- and long-term aspects for the benefit of the global
population on the whole.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>All the authors acknowledge and thank their respective Institutes and Universities. YSM
acknowledges the Education Division, ICAR, GoI for National Fellowship.</p></ack><sec id="s0002" disp-level="1"><title>Author contributions</title><p>All the authors substantially contributed to the conception, compilation of data, checking
and approving the final version of the manuscript, and agree to be accountable for its
contents.</p></sec><sec id="s0003" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>All authors declare that there exist no commercial or financial relationships that could,
in any way, lead to a potential conflict of interest.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paules</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Marston</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Fauci</surname><given-names>AS.</given-names></name></person-group>
<article-title>Coronavirus infections-more than just the common cold</article-title>.
<source>JAMA</source>.
<year>2020</year>;<volume>323</volume>(<issue>8</issue>):<fpage>707</fpage>
<comment>[published online ahead of print, 2020 Jan 23]</comment>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.0757</pub-id>.<pub-id pub-id-type="pmid">31971553</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Munster</surname><given-names>VJ</given-names></name></person-group>
<article-title>SARS and
MERS: recent insights into emerging coronaviruses</article-title>. <source>Nature Rev
Microbiol</source>.
<year>2016</year>;<volume>14</volume>(<issue>8</issue>):<fpage>523</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id>.<pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Sircar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Dadar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chaicumpa</surname><given-names>W</given-names></name></person-group>
<article-title>Emerging
novel coronavirus (2019-nCoV)&#x02014;current scenario, evolutionary perspective based on genome
analysis and recent developments</article-title>. <source>Vet Quart</source>.
<year>2020a</year>;<volume>40</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>76</lpage>.
doi:<pub-id pub-id-type="doi">10.1080/01652176.2020.1727993</pub-id>.</mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sircar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Chaicumpa</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Bonilla-Aldana</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Morales</surname><given-names>AJR</given-names></name></person-group>
<article-title>Coronavirus disease 2019&#x02013;COVID-19</article-title>.
<source>Preprints</source>. <year>2020b</year>:<fpage>2020030001</fpage>. doi:<pub-id pub-id-type="doi">10.20944/preprints202003.0001.v2</pub-id>.</mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>WHO
Coronavirus disease (COVID-19) Situation Report No. 201</collab></person-group>
(<comment>As on</comment>
<day>8th</day>
<month>8</month>
<year>2020</year>). <date-in-citation>[accessed 2020 <month>8</month><day>9</day>]</date-in-citation>
<ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200808-covid-19-sitrep-201.pdf?sfvrsn=121bb855_2">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200808-covid-19-sitrep-201.pdf?sfvrsn=121bb855_2</ext-link></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peeri</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Shrestha</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>MS</given-names></name>, Zaki R, Tan Z, Bibi S, Baghbanzadeh M,
Aghamohammadi N, Zhang W, Haque U</person-group>
<article-title>The SARS, MERS and
novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats:
what lessons have we learned?</article-title>
<source>Int J Epidemiol</source>. <year>2020</year>;<fpage>dyaa033</fpage>
<comment>[published online ahead of print, 2020 Feb 22]</comment>. doi:<pub-id pub-id-type="doi">10.1093/ije/dyaa033</pub-id>.</mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Sircar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vinodhkumar</surname><given-names>OR</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sah</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rabaan</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Morales</surname><given-names>AJR</given-names></name>, <name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name></person-group>
<article-title>Emerging
coronavirus disease (COVID-19), a pandemic public health emergency with animal linkages:
current status update</article-title>. <source>Preprints</source>.
<year>2020b</year>:<fpage>2020030343</fpage>. doi:<pub-id pub-id-type="doi">10.20944/preprints202003.0343.v1</pub-id>.</mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kok</surname><given-names>K-H</given-names></name>, <name name-style="western"><surname>To</surname><given-names>KKW</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xing</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yip</surname><given-names>CCY</given-names></name>, <name name-style="western"><surname>Poon</surname><given-names>RWS</given-names></name>, et al</person-group>
<article-title>A
familial cluster of pneumonia associated with the 2019 novel coronavirus indicating
person-to-person transmission: a study of a family cluster</article-title>.
<source>Lancet</source>.
<year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>514</fpage>&#x02013;<lpage>23</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id>.<pub-id pub-id-type="pmid">31986261</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ruan</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected
patients</article-title>. <source>N Engl J Med</source>.
<year>2020</year>;<volume>382</volume>(<issue>12</issue>):<fpage>1177</fpage>&#x02013;<lpage>79</lpage>.
doi:<pub-id pub-id-type="doi">10.1056/NEJMc2001737</pub-id>.<pub-id pub-id-type="pmid">32074444</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Ong</surname><given-names>SWX</given-names></name>, <name name-style="western"><surname>Kalimuddin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Low</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Loh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>O-T</given-names></name>, <name name-style="western"><surname>Marimuthu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ang</surname><given-names>LW</given-names></name>, <name name-style="western"><surname>Mak</surname><given-names>TM</given-names></name>, et al</person-group>
<article-title>Epidemiologic features and clinical course of patients infected with
SARS-CoV-2 in Singapore</article-title>. <source>JAMA</source>.
<year>2020</year>;<volume>323</volume>(<issue>15</issue>):<fpage>1488</fpage>&#x02013;<lpage>94</lpage>.
<comment>[published online ahead of print, 2020 Mar 3] [published correction appears in
JAMA. doi: 10.1001/jama.2020.4372]</comment>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.3204</pub-id>.<pub-id pub-id-type="pmid">32125362</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peiris</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name>, <name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>St&#x000f6;hr</surname><given-names>K</given-names></name></person-group>
<article-title>The severe
acute respiratory syndrome</article-title>. <source>N Engl J Med</source>.
<year>2003</year>;<volume>349</volume>(<issue>25</issue>):<fpage>2431</fpage>&#x02013;<lpage>41</lpage>.
doi:<pub-id pub-id-type="doi">10.1056/NEJMra032498</pub-id>.<pub-id pub-id-type="pmid">14681510</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sharun</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name>, Dadar M, Malik YS, Singh KP, Chaicumpa
W</person-group>
<article-title>COVID-19, an emerging coronavirus infection: advances
and prospects in designing and developing vaccines, immunotherapeutics, and
therapeutics</article-title>. <source>Hum Vaccin Immunother</source>.
<year>2020</year>;<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <comment>[published online ahead of
print, 2020 Mar 18]</comment>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2020.1735227</pub-id>.</mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>YZ</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name></person-group>
<article-title>A genomic
perspective on the origin and emergence of SARS-CoV-2</article-title>.
<source>Cell</source>.
<year>2020</year>;<volume>181</volume>(<issue>2</issue>):<fpage>223</fpage>&#x02013;<lpage>27</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.03.035</pub-id>.<pub-id pub-id-type="pmid">32220310</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lagniton</surname><given-names>PNP</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>RH</given-names></name></person-group>
<article-title>COVID-19:
what has been learned and to be learned about the novel coronavirus
disease</article-title>. <source>Int J Biol Sci</source>.
<year>2020</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1753</fpage>&#x02013;<lpage>66</lpage>.
<comment>Published 2020 Mar 15</comment>. doi:<pub-id pub-id-type="doi">10.7150/ijbs.45134</pub-id>.<pub-id pub-id-type="pmid">32226295</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shann</surname><given-names>F</given-names></name></person-group>
<article-title>Nonspecific
effects of vaccines and the reduction of mortality in children</article-title>.
<source>Clin Therapeut</source>.
<year>2013</year>;<volume>35</volume>(<issue>2</issue>):<fpage>109</fpage>&#x02013;<lpage>14</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.clinthera.2013.01.007</pub-id>.</mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moorlag</surname><given-names>SJCFM</given-names></name>, <name name-style="western"><surname>Arts</surname><given-names>RJW</given-names></name>, <name name-style="western"><surname>van Crevel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group>
<article-title>Non-specific effects of BCG vaccine on viral infections</article-title>.
<source>Clin Microbiol Infect</source>.
<year>2019</year>;<volume>25</volume>(<issue>12</issue>):<fpage>1473</fpage>&#x02013;<lpage>78</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2019.04.020</pub-id>.<pub-id pub-id-type="pmid">31055165</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinnijenhuis</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Quintin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Preijers</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Joosten</surname><given-names>LAB</given-names></name>, <name name-style="western"><surname>Ifrim</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jacobs</surname><given-names>C</given-names></name>, <name name-style="western"><surname>van Loenhout</surname><given-names>J</given-names></name>, <name name-style="western"><surname>de Jong</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Stunnenberg</surname><given-names>HG</given-names></name>, et al</person-group>
<article-title>Bacille calmette-guerin induces NOD2-dependent nonspecific protection
from reinfection via epigenetic reprogramming of monocytes</article-title>. <source>Proc
Natl Acad Sci USA</source>.
<year>2012</year>;<volume>109</volume>(<issue>43</issue>):<fpage>17537</fpage>&#x02013;<lpage>42</lpage>.
doi:<pub-id pub-id-type="doi">10.1073/pnas.1202870109</pub-id>.<pub-id pub-id-type="pmid">22988082</pub-id></mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>W</given-names></name>, Wu W, Chen S, Zhang W, Duan
G</person-group>
<article-title>Virology, Epidemiology, Pathogenesis, and Control of
COVID-19. Viruses</article-title>.
<year>2020</year>;<volume>12</volume>(<issue>4</issue>):<fpage>E372</fpage>
<comment>Published 2020 Mar 27</comment>. doi:<pub-id pub-id-type="doi">10.3390/v12040372</pub-id>.</mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayoub</surname><given-names>BM</given-names></name></person-group>
<article-title>COVID-19
vaccination clinical trials should consider multiple doses of BCG</article-title>.
<source>Pharmazie</source>.
<year>2020</year>;<volume>75</volume>(<issue>4</issue>):<fpage>159</fpage>. doi:<pub-id pub-id-type="doi">10.1691/ph.2020.0444</pub-id>.<pub-id pub-id-type="pmid">32295694</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alakwaa</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Gilbert</surname><given-names>JA</given-names></name></person-group>
<article-title>Repurposing
Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing
Data</article-title>. <source>Msystems</source>.
<year>2020</year>;<volume>5</volume>(<issue>2</issue>):<fpage>e00297</fpage>&#x02013;<lpage>20</lpage>.
doi:<pub-id pub-id-type="doi">10.1128/mSystems.00297-20</pub-id>.<pub-id pub-id-type="pmid">32291351</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>TY</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>B</given-names></name></person-group>
<article-title>Meeting the
Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for
COVID-19</article-title>. <source>Med Drug Discov</source>.
<year>2020</year>;<volume>5</volume>:<fpage>100036</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.medidd.2020.100036</pub-id>.<pub-id pub-id-type="pmid">32292908</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picot</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Marty</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bienvenu</surname><given-names>A-L</given-names></name>, <name name-style="western"><surname>Blumberg</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Dupouy-Camet</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Carnevale</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Daniel-Ribeiro</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Mas-Coma</surname><given-names>S</given-names></name>, et al</person-group>
<article-title>Coalition: advocacy for prospective clinical trials to test the
post-exposure potential of hydroxychloroquine against COVID-19</article-title>.
<source>One Health</source>. <year>2020</year>;<volume>9</volume>:<fpage>100131</fpage>
<comment>[published online ahead of print, 2020 Apr 4]</comment>. doi:<pub-id pub-id-type="doi">10.1016/j.onehlt.2020.100131</pub-id>.<pub-id pub-id-type="pmid">32292817</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caly</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Druce</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Catton</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Jans</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group>
<article-title>The
FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in
vitro</article-title>. <source>Antiviral Res</source>.
<year>2020</year>;<volume>178</volume>:<fpage>104787</fpage>
<comment>[published online
ahead of print, 2020 Apr 3]</comment>. doi:<pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id>.<pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patr&#x000ec;</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Fabbrocini</surname><given-names>G</given-names></name></person-group>
<article-title>Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19
chemoprophylaxis and treatment?</article-title>
<source>J Am Acad Dermatol</source>.
<year>2020</year>;<volume>S0190-9622</volume>(<issue>20</issue>):<fpage>30557</fpage>
<comment>[published online ahead of print, 2020 Apr 10]</comment>. doi:<pub-id pub-id-type="doi">10.1016/j.jaad.2020.04.017</pub-id>.</mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damle</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Vourvahis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Leaney</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Corrigan</surname><given-names>B</given-names></name></person-group>
<article-title>Clinical
Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in
COVID-19</article-title>. <source>Clin Pharmacol Ther</source>.
<year>2020</year>;<volume>108</volume>(<issue>2</issue>):<fpage>201</fpage>&#x02013;<lpage>11</lpage>.
<comment>[published online ahead of print, 2020 Apr 17]</comment>. doi:<pub-id pub-id-type="doi">10.1002/cpt.1857</pub-id>.<pub-id pub-id-type="pmid">32302411</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ford</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vitoria</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rangaraj</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Norris</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Calmy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Doherty</surname><given-names>M</given-names></name></person-group>
<article-title>Systematic
review of the efficacy and safety of antiretroviral drugs against SARS, MERS or
COVID-19: initial assessment</article-title>. <source>J Int AIDS Soc</source>.
<year>2020</year>;<volume>23</volume>(<issue>4</issue>):<fpage>e25489</fpage>.
doi:<pub-id pub-id-type="doi">10.1002/jia2.25489</pub-id>.<pub-id pub-id-type="pmid">32293807</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group>
<article-title>Potential
interventions for novel coronavirus in China: a systemic review</article-title>.
<source>J Med Virol</source>.
<year>2020</year>;<volume>92</volume>(<issue>5</issue>):<fpage>479</fpage>&#x02013;<lpage>90</lpage>.
doi:<pub-id pub-id-type="doi">10.1002/jmv.25707</pub-id>.<pub-id pub-id-type="pmid">32052466</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yavuz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>&#x000dc;nal</surname><given-names>S</given-names></name></person-group>
<article-title>Antiviral
treatment of COVID-19</article-title>. <source>Turkish J Med Sci</source>.
<year>2020</year>;<volume>50</volume>(<issue>SI&#x02013;1</issue>):<fpage>611</fpage>&#x02013;<lpage>19</lpage>.
doi:<pub-id pub-id-type="doi">10.3906/sag-2004-145</pub-id>.</mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Patankar</surname><given-names>P</given-names></name></person-group>
<article-title>Emerging
pharmacotherapies for COVID-19</article-title>. <source>Biomed Pharmacother</source>.
<year>2020</year>
<month>5</month>;<volume>14</volume>:<fpage>110267</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110267</pub-id>.</mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachanova</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Bishop</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Dahi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dholaria</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Grupp</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Lattin</surname><given-names>BH</given-names></name>, <name name-style="western"><surname>Janakiram</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Maziarz</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>McGuirk</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Nastoupil</surname><given-names>LJ</given-names></name></person-group>
<article-title>CAR T Cell
Therapy During the COVID-19 Pandemic</article-title>. <source>Biol Blood Marrow
Trans</source>.
<year>2020</year>;<volume>26</volume>(<issue>7</issue>):<fpage>1239</fpage>&#x02013;<lpage>46</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.bbmt.2020.04.008</pub-id>.</mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>RC</given-names></name></person-group>
<article-title>Stem
Cell-Based Therapy for Coronavirus Disease 2019</article-title>. <source>Stem Cells
Dev</source>.
<year>2020</year>;<volume>29</volume>(<issue>11</issue>):<fpage>679</fpage>&#x02013;<lpage>81</lpage>.
<comment>[published online ahead of print, 2020 Apr 17]</comment>. doi:<pub-id pub-id-type="doi">10.1089/scd.2020.0071</pub-id>.<pub-id pub-id-type="pmid">32292113</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warren</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Panchal</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Stuthman</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Garza</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Van Tongeren</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Retterer</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Eaton</surname><given-names>BP</given-names></name>, <name name-style="western"><surname>Pegoraro</surname><given-names>G</given-names></name>, et al</person-group>
<article-title>Protection against filovirus diseases by a novel broad-spectrum
nucleoside analogue BCX4430</article-title>. <source>Nature</source>. <year>2014</year>
<month>4</month>
<day>17</day>;<volume>508</volume>(<issue>7496</issue>):<fpage>402</fpage>&#x02013;<lpage>05</lpage>.
doi:<pub-id pub-id-type="doi">10.1038/nature13027</pub-id>.<pub-id pub-id-type="pmid">24590073</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawase</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shirato</surname><given-names>K</given-names></name>, <name name-style="western"><surname>van der Hoek</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Taguchi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Matsuyama</surname><given-names>S</given-names></name></person-group>
<article-title>Simultaneous
treatment of human bronchial epithelial cells with serine and cysteine protease
inhibitors prevents severe acute respiratory syndrome coronavirus entry</article-title>.
<source>J Virol</source>. <year>2012</year>
<month>6</month>;<volume>86</volume>(<issue>12</issue>):<fpage>6537</fpage>&#x02013;<lpage>45</lpage>.
doi:<pub-id pub-id-type="doi">10.1128/JVI.00094-12</pub-id>.<pub-id pub-id-type="pmid">22496216</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>X</given-names></name>, et al</person-group>
<article-title>Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2)
associated with human respiratory disease: detection, mechanisms and
treatment</article-title>. <source>Int J Antimicrob Agents</source>. <year>2020</year>
<month>3</month>;<volume>29</volume>(<issue>5</issue>):<fpage>105950</fpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105950</pub-id>.</mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zuo</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Poon</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>Potent neutralization of MERS-CoV by human neutralizing monoclonal
antibodies to the viral spike glycoprotein</article-title>. <source>Sci Transl
Med</source>. <year>2014</year>
<month>4</month>
<day>30</day>;<volume>6</volume>(<issue>234</issue>):<fpage>234ra59</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3008140</pub-id>.</mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jawhara</surname><given-names>S</given-names></name></person-group>
<article-title>Could
Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against
COVID-19 and Strengthen the Immune System of New Patients?</article-title>
<source>Int J Mol Sci</source>.
<year>2020</year>;<volume>21</volume>(<issue>7</issue>):<fpage>E2272</fpage>
<comment>Published 2020 Mar 25</comment>. doi:<pub-id pub-id-type="doi">10.3390/ijms21072272</pub-id>.<pub-id pub-id-type="pmid">32218340</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA
Vaccine (mRNA-1273) Against Novel Coronavirus</collab></person-group>
<date-in-citation>[accessed <month>5</month><day>19</day>, 2020]</date-in-citation>
<ext-link ext-link-type="uri" xlink:href="https://investors.modernatx.com/node/8466/pdf">https://investors.modernatx.com/node/8466/pdf</ext-link></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>YH</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>XH</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>L-H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W-J</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J-X</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S-P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B-S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, et al</person-group>
<article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus
type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised,
first-in-human trial</article-title>. <source>Lancet</source>.
<year>2020</year>;<volume>395</volume>(<issue>10240</issue>):<fpage>1845</fpage>&#x02013;<lpage>54</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id>.<pub-id pub-id-type="pmid">32450106</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>TRF</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ramos</surname><given-names>S</given-names></name>, Elwood D, Zhu X, Yan J, Gary EN, Walker
SN, Schultheis K, Purwar M, et al</person-group>
<article-title>Immunogenicity of a DNA
vaccine candidate for COVID-19</article-title>. <source>Nat Commun</source>.
<year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>2601</fpage>
<comment>Published 2020 May 20</comment>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-16505-0</pub-id>.<pub-id pub-id-type="pmid">32433465</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelidou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Diray-Arce</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Conti</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Smolen</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>van Haren</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Dowling</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Husson</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>O</given-names></name></person-group>
<article-title>BCG as a
case study for precision vaccine development: lessons from vaccine heterogeneity,
trained immunity, and immune ontogeny</article-title>. <source>Front Microbiol</source>.
<year>2020</year>;<volume>11</volume>:<fpage>332</fpage>
<comment>Published 2020 Mar
11</comment>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2020.00332</pub-id>.<pub-id pub-id-type="pmid">32218774</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raviglione</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Pio</surname><given-names>A</given-names></name></person-group>
<article-title>Evolution of
WHO policies for tuberculosis control, 1948-2001</article-title>.
<source>Lancet</source>.
<year>2002</year>;<volume>359</volume>(<issue>9308</issue>):<fpage>775</fpage>&#x02013;<lpage>80</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(02)07880-7</pub-id>.<pub-id pub-id-type="pmid">11888605</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooft van Huijsduijnen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kojima</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Okabe</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sato</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Akahata</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>TNC</given-names></name>, <name name-style="western"><surname>Katsuno</surname><given-names>K</given-names></name></person-group>
<article-title>Reassessing
therapeutic antibodies for neglected and tropical diseases</article-title>. <source>PLoS
Negl Trop Dis</source>.
<year>2020</year>;<volume>14</volume>(<issue>1</issue>):<fpage>e0007860</fpage>
<comment>Published 2020 Jan 30</comment>. doi:<pub-id pub-id-type="doi">10.1371/journal.pntd.0007860</pub-id>.<pub-id pub-id-type="pmid">31999695</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Abri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kasaeva</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Migliori</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Goletti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zenner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Denholm</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Al Maani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cirillo</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Sch&#x000f6;n</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lilleb&#x000e6;k</surname><given-names>T</given-names></name>, et al</person-group>
<article-title>Tools
to implement the world health organization end TB strategy: addressing common challenges
in high and low endemic countries</article-title>. <source>Int J Infect Dis</source>.
<year>2020</year>;<volume>92S</volume>:<fpage>S60</fpage>&#x02013;<lpage>S68</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.ijid.2020.02.042</pub-id>.<pub-id pub-id-type="pmid">32114195</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsang</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Doba&#x000f1;o</surname><given-names>C</given-names></name>, <name name-style="western"><surname>VanDamme</surname><given-names>P</given-names></name>, Moncunill G, Marchant A, Othman RB,
Sadarangani M, Koff W, Kollmann TR</person-group>
<article-title>Improving
vaccine-induced immunity: can baseline predict outcome?</article-title>
<source>Trends Immunol</source>. 2020;41(6):457-465. doi:<pub-id pub-id-type="doi">10.1016/j.it.2020.04.001</pub-id>.</mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trunz</surname><given-names>BB</given-names></name>, <name name-style="western"><surname>Fine</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dye</surname><given-names>C</given-names></name></person-group>
<article-title>Effect of
BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide:
a meta-analysis and assessment of cost-effectiveness</article-title>.
<source>Lancet</source>.
<year>2006</year>;<volume>367</volume>(<issue>9517</issue>):<fpage>1173</fpage>&#x02013;<lpage>80</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(06)68507-3</pub-id>.<pub-id pub-id-type="pmid">16616560</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumner</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Penn-Nicholson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hatherill</surname><given-names>M</given-names></name>, <name name-style="western"><surname>White</surname><given-names>RG</given-names></name></person-group>
<article-title>Potential
population level impact on tuberculosis incidence of using an mRNA expression signature
correlate-of-risk test to target tuberculosis preventive therapy</article-title>.
<source>Sci Rep</source>.
<year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>11126</fpage>
<comment>Published 2019 Jul 31</comment>. doi:<pub-id pub-id-type="doi">10.1038/s41598-019-47645-z</pub-id>.<pub-id pub-id-type="pmid">31366947</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangtani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Abubakar</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ariti</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Beynon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Pimpin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fine</surname><given-names>PEM</given-names></name>, <name name-style="western"><surname>Rodrigues</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Lipman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Whiting</surname><given-names>PF</given-names></name>, et al</person-group>
<article-title>Protection by BCG vaccine against tuberculosis: a systematic review of
randomized controlled trials</article-title>. <source>Clin Infect Dis</source>.
<year>2014</year>;<volume>58</volume>(<issue>4</issue>):<fpage>470</fpage>&#x02013;<lpage>80</lpage>.
doi:<pub-id pub-id-type="doi">10.1093/cid/cit790</pub-id>.<pub-id pub-id-type="pmid">24336911</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abubakar</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pimpin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ariti</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Beynon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mangtani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sterne</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fine</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Lipman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Elliman</surname><given-names>D</given-names></name>, et al</person-group>
<article-title>Systematic review and meta-analysis of the current evidence on the
duration of protection by bacillus Calmette-Gu&#x000e9;rin vaccination against
tuberculosis</article-title>. <source>Health Technol Assess</source>.
<year>2013</year>;<volume>17</volume>(<issue>37</issue>):<fpage>1</fpage>&#x02013;<lpage>vi</lpage>.
doi:<pub-id pub-id-type="doi">10.3310/hta17370</pub-id>.</mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sanderson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>White</surname><given-names>RG</given-names></name></person-group>
<article-title>Potential
effect of age of BCG vaccination on global paediatric tuberculosis mortality: a
modelling study</article-title>. <source>Lancet Glob Health</source>.
<year>2019</year>;<volume>7</volume>(<issue>12</issue>):<fpage>e1655</fpage>&#x02013;<lpage>e1663</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(19)30444-9</pub-id>.<pub-id pub-id-type="pmid">31708146</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zwerling</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Behr</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brewer</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Menzies</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pai</surname><given-names>M</given-names></name></person-group>
<article-title>The BCG
world atlas: a database of global BCG vaccination policies and
practices</article-title>. <source>PLoS Med</source>.
<year>2011</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e1001012</fpage>.
doi:<pub-id pub-id-type="doi">10.1371/journal.pmed.1001012</pub-id>.<pub-id pub-id-type="pmid">21445325</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butkeviciute</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>SG</given-names></name></person-group>
<article-title>Heterologous effects of infant BCG vaccination: potential mechanisms of
immunity</article-title>. <source>Future Microbiol</source>.
<year>2018</year>;<volume>13</volume>(<issue>10</issue>):<fpage>1193</fpage>&#x02013;<lpage>208</lpage>.
doi:<pub-id pub-id-type="doi">10.2217/fmb-2018-0026</pub-id>.<pub-id pub-id-type="pmid">30117744</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redelman-Sidi</surname><given-names>G</given-names></name></person-group>
<article-title>Could BCG be
used to protect against COVID-19?</article-title>
<source>Nat Rev Urol</source>. <year>2020</year>:<page-range>1&#x02010;2</page-range>. doi:<pub-id pub-id-type="doi">10.1038/s41585-020-0325-9</pub-id>.</mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Meena</surname><given-names>J</given-names></name></person-group>
<article-title>Demystifying
BCG Vaccine and COVID-19 Relationship</article-title>. <source>Indian Pediatr</source>.
<year>2020</year>;PII:<fpage>S097475591600168</fpage>
<comment>[published online ahead
of print, 2020 Apr 30]</comment><pub-id pub-id-type="pmid">32358227</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Covi&#x000e1;n</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fern&#x000e1;ndez-Fierro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Retamal-D&#x000ed;az</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D&#x000ed;az</surname><given-names>FE</given-names></name>, <name name-style="western"><surname>Vasquez</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Lay</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Riedel</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Gonz&#x000e1;lez</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Bueno</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Kalergis</surname><given-names>AM</given-names></name>, et al</person-group>
<article-title>BCG-induced cross-protection and development of trained immunity:
implication for vaccine design</article-title>. <source>Front Immunol</source>.
<year>2019</year>;<volume>10</volume>:<fpage>2806</fpage>
<comment>Published 2019 Nov
29</comment>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2019.02806</pub-id>.<pub-id pub-id-type="pmid">31849980</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morales</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eidinger</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bruce</surname><given-names>AW</given-names></name></person-group>
<article-title>Intracavitary Bacillus Calmette-Guerin in the treatment of superficial
bladder tumors</article-title>. <source>J Urol</source>.
<year>1976</year>;<volume>116</volume>(<issue>2</issue>):<fpage>180</fpage>&#x02013;<lpage>83</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/S0022-5347(17)58737-6</pub-id>.<pub-id pub-id-type="pmid">820877</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redelman-Sidi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Glickman</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Bochner</surname><given-names>BH</given-names></name></person-group>
<article-title>The
mechanism of action of BCG therapy for bladder cancer&#x02014;a current
perspective</article-title>. <source>Nat Rev Urol</source>.
<year>2014</year>;<volume>11</volume>(<issue>3</issue>):<fpage>153</fpage>&#x02013;<lpage>62</lpage>.
doi:<pub-id pub-id-type="doi">10.1038/nrurol.2014.15</pub-id>.<pub-id pub-id-type="pmid">24492433</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandroff</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>O&#x02019;Donnell</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>James</surname><given-names>K</given-names></name></person-group>
<article-title>BCG
immunotherapy of bladder cancer: 20 years on</article-title>. <source>Lancet</source>.
<year>1999</year>;<volume>353</volume>(<issue>9165</issue>):<fpage>1689</fpage>&#x02013;<lpage>94</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(98)07422-4</pub-id>.<pub-id pub-id-type="pmid">10335805</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Miyazaki</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Joraku</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nishiyama</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Akaza</surname><given-names>H</given-names></name></person-group>
<article-title>Bacillus
Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and
perspectives on engineered BCG vaccine</article-title>. <source>Cancer Sci</source>.
<year>2013</year>;<volume>104</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02013;<lpage>27</lpage>.
doi:<pub-id pub-id-type="doi">10.1111/cas.12075</pub-id>.<pub-id pub-id-type="pmid">23181987</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Schlitzer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Placek</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Joosten</surname><given-names>LAB</given-names></name>, <name name-style="western"><surname>Schultze</surname><given-names>JL</given-names></name></person-group>
<article-title>Innate and
adaptive immune memory: an evolutionary continuum in the host&#x02019;s response to
pathogens</article-title>. <source>Cell Host Microbe</source>.
<year>2019</year>;<volume>25</volume>(<issue>1</issue>):<fpage>13</fpage>&#x02013;<lpage>26</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.chom.2018.12.006</pub-id>.<pub-id pub-id-type="pmid">30629914</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van&#x02019;t Wout</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Poell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>van Furth</surname><given-names>R</given-names></name></person-group>
<article-title>The role of
BCG/PPD-activated macrophages in resistance against systemic candidiasis in
mice</article-title>. <source>Scand J Immunol</source>.
<year>1992</year>;<volume>36</volume>(<issue>5</issue>):<fpage>713</fpage>&#x02013;<lpage>19</lpage>.
doi:<pub-id pub-id-type="doi">10.1111/j.1365-3083.1992.tb03132.x</pub-id>.<pub-id pub-id-type="pmid">1439583</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kaufmann</surname><given-names>SHE</given-names></name></person-group>
<article-title>Novel
vaccination strategies against tuberculosis</article-title>. <source>Cold Spring Harb
Perspect Med</source>.
<year>2014</year>;<volume>4</volume>(<issue>6</issue>):<fpage>a018523</fpage>.
doi:<pub-id pub-id-type="doi">10.1101/cshperspect.a018523</pub-id>.<pub-id pub-id-type="pmid">24890836</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertholet</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ireton</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Kahn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guderian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mohamath</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Stride</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Laughlin</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Baldwin</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Vedvick</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Coler</surname><given-names>RN</given-names></name>, et al</person-group>
<article-title>Identification of human T cell antigens for the development of vaccines
against mycobacterium tuberculosis</article-title>. <source>J Immunol</source>.
<year>2008</year>;<volume>181</volume>(<issue>11</issue>):<fpage>7948</fpage>&#x02013;<lpage>57</lpage>.
doi:<pub-id pub-id-type="doi">10.4049/jimmunol.181.11.7948</pub-id>.<pub-id pub-id-type="pmid">19017986</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Neill</surname><given-names>LAJ</given-names></name>, <name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group>
<article-title>BCG-
induced trained immunity: can it offer protection against COVID-19?</article-title>
<source>Nature Rev</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1038/s41577-020-0337-</pub-id>.</mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Kooyk</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Engering</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lekkerkerker</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Ludwig</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Geijtenbeek</surname><given-names>TB</given-names></name></person-group>
<article-title>Pathogens
use carbohydrates to escape immunity induced by dendritic cells</article-title>.
<source>Curr Opin Immunol</source>.
<year>2004</year>;<volume>16</volume>(<issue>4</issue>):<fpage>488</fpage>&#x02013;<lpage>93</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.coi.2004.05.010</pub-id>.<pub-id pub-id-type="pmid">15245744</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name></person-group>
<article-title>Innate
immunity and adjuvants</article-title>. <source>Philos Trans R Soc Lond B Biol
Sci</source>.
<year>2011</year>;<volume>366</volume>(<issue>1579</issue>):<fpage>2748</fpage>&#x02013;<lpage>55</lpage>.
doi:<pub-id pub-id-type="doi">10.1098/rstb.2011.0106</pub-id>.<pub-id pub-id-type="pmid">21893536</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>
<article-title>Regulation
of adaptive immunity by the innate immune system</article-title>.
<source>Science</source>.
<year>2010</year>;<volume>327</volume>(<issue>5963</issue>):<fpage>291</fpage>&#x02013;<lpage>95</lpage>.
doi:<pub-id pub-id-type="doi">10.1126/science.1183021</pub-id>.<pub-id pub-id-type="pmid">20075244</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyssens</surname><given-names>IC</given-names></name>, <name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group>
<article-title>Heterologous effects of vaccination and trained immunity</article-title>.
<source>Clin Microbiol Infect</source>.
<year>2019</year>;<volume>25</volume>(<issue>12</issue>):<fpage>1457</fpage>&#x02013;<lpage>58</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.cmi.2019.05.024</pub-id>.<pub-id pub-id-type="pmid">31158520</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanner</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Villarreal-Ramos</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Vordermeier</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>McShane</surname><given-names>H</given-names></name></person-group>
<article-title>The humoral
immune response to BCG vaccination</article-title>. <source>Front Immunol</source>.
<year>2019</year>;<volume>10</volume>:<fpage>1317</fpage>
<comment>Published 2019 Jun
11</comment>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2019.01317</pub-id>.<pub-id pub-id-type="pmid">31244856</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerra-Maupome</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vang</surname><given-names>DX</given-names></name>, <name name-style="western"><surname>McGill</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Basu</surname><given-names>J</given-names></name></person-group>
<article-title>Aerosol
vaccination with bacille calmette-guerin induces a trained innate immune phenotype in
calves</article-title>. <source>PLoS One</source>.
<year>2019</year>;<volume>14</volume>(<issue>2</issue>):<fpage>e0212751</fpage>
<comment>Published 2019 Feb 22</comment>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0212751</pub-id>.<pub-id pub-id-type="pmid">30794653</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taranc&#x000f3;n</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dom&#x000ed;nguez-Andr&#x000e9;s</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Uranga</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Groh</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Domenech</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gonz&#x000e1;lez-Camacho</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Riksen</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Aguilo</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yuste</surname><given-names>J</given-names></name>, et al</person-group>
<article-title>New
live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers
protection against experimental lethal pneumonia</article-title>. <source>PLoS
Pathog</source>.
<year>2020</year>;<volume>16</volume>(<issue>4</issue>):<fpage>e1008404</fpage>
<comment>Published 2020 Apr 2</comment>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1008404</pub-id>.<pub-id pub-id-type="pmid">32240273</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabaan</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Al-Ahmed</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Haque</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sah</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yatoo</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Bonilla-Aldana</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Rodriguez-Morales</surname><given-names>AJ</given-names></name>, et al</person-group>
<article-title>SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative
overview</article-title>. <source>Infez Med</source>.
<year>2020</year>;<volume>28</volume>(<issue>2</issue>):<fpage>174</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">32275259</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Salem</surname><given-names>ML</given-names></name></person-group>
<article-title>Routine
childhood immunization may protect against COVID-19</article-title>. <source>Med
Hypotheses</source>. <year>2020</year>;<volume>140</volume>:<fpage>109689</fpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.mehy.2020.109689</pub-id>.<pub-id pub-id-type="pmid">32240961</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Reandelar</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Fasciglione</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Roumenova</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Otazu</surname><given-names>GH</given-names></name></person-group>
<article-title>Correlation
between universal BCG vaccination policy and reduced morbidity and mortality for
COVID-19: an epidemiological study</article-title>. <source>medRxiv</source>.
<year>2020</year>. doi:<pub-id pub-id-type="doi">10.1101/2020.03.24.20042937</pub-id>.</mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>rubau</surname><given-names>ND</given-names></name></person-group>
<article-title>Why does
Japan have so few cases of COVID-19?</article-title>
<source>EMBO Mol Med</source>.
<year>2020</year>;<volume>12</volume>(<issue>5</issue>):<fpage>e12481</fpage>.
doi:<pub-id pub-id-type="doi">10.15252/emmm.202012481</pub-id>.<pub-id pub-id-type="pmid">32275804</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>BR</given-names></name>, <name name-style="western"><surname>Gandharva</surname><given-names>R</given-names></name></person-group>
<article-title>Are BCG
vaccination, population density, median age and poverty important determinants of
COVID-19 pandemic spread, morbidity and mortality?</article-title> Researchgate.
<year>2020</year>. doi:<pub-id pub-id-type="doi">10.13140/RG.2.2.21116.49282</pub-id>.</mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iqbal</surname><given-names>NT</given-names></name>, <name name-style="western"><surname>Hussain</surname><given-names>R</given-names></name></person-group>
<article-title>Non-specific
immunity of BCG vaccine: a perspective of BCG immunotherapy</article-title>.
<source>Trials Vaccinol</source>.
<year>2014</year>;<volume>3</volume>:<fpage>143</fpage>&#x02013;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.trivac.2014.08.002</pub-id>.</mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Udani</surname><given-names>PM</given-names></name></person-group>
<article-title>BCG
vaccination in India and tuberculosis in children: newer facets</article-title>.
<source>Indian J Pediat</source>.
<year>1994</year>;<volume>1994</volume>(<issue>61</issue>):<fpage>451</fpage>&#x02013;<lpage>62</lpage>.
doi:<pub-id pub-id-type="doi">10.1007/BF02751703</pub-id>.</mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lahariya</surname><given-names>C</given-names></name></person-group>
<article-title>A brief
history of vaccines &#x00026; vaccination in India</article-title>. <source>Indian J Med
Res</source>.
<year>2014</year>;<volume>139</volume>:<fpage>491</fpage>.<pub-id pub-id-type="pmid">24927336</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuroda</surname><given-names>N</given-names></name></person-group>
<article-title>Demand for
BCG vaccine due to unproven claims of its role in preventing COVID-19 is causing
shortages of vaccines for infants in Japan</article-title>. <source>Pediatr Infect Dis
J</source>. <year>2020</year>:<volume>Publish Ahead of Print</volume>. doi:<pub-id pub-id-type="doi">10.1097/INF.0000000000002724</pub-id>.</mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Connor</surname><given-names>E</given-names></name>, <name name-style="western"><surname>The</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kamat</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Lawrentschuk</surname><given-names>N</given-names></name></person-group>
<article-title>Bacillus
Calmette Gu&#x000b4;erin (BCG) vaccination use in the fight against COVID-19 &#x02013; what&#x02019;s old is new
again?</article-title>
<source>Future Oncol</source>.
<year>2020</year>;<volume>16</volume>(<issue>19</issue>):<fpage>1323</fpage>&#x02013;<lpage>25</lpage>.
<comment>(Epub ahead of print)</comment>. doi:<pub-id pub-id-type="doi">10.2217/fon-2020-0381</pub-id>.<pub-id pub-id-type="pmid">32406253</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawton</surname><given-names>G</given-names></name></person-group>
<article-title>Trials of
BCG vaccine will test for covid-19 protection</article-title>. <source>New Sci</source>.
<year>2020</year>;<volume>246</volume>(<issue>3280</issue>):<fpage>9</fpage>.
doi:<pub-id pub-id-type="doi">10.1016/S0262-4079(20)30836-8</pub-id>.</mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>U.S. National Library of Medicine,
ClinicalTrials.gov</collab></person-group>
<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04348370">https://clinicaltrials.gov/ct2/show/NCT04348370</ext-link></mixed-citation></ref></ref-list></back></article>